All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Zasocitinib (TAK-279) in psoriasis: Results from a phase IIb trial
By Ella Dixon
|
Zasocitinib (formerly TAK-279), a tyrosine kinase 2 (TYK2) inhibitor, has been investigated for the treatment of psoriasis and psoriatic arthritis.1 A phase IIb randomized, multicenter study compared four doses of zasocitinib (2, 5, 15, and 30 mg) with placebo for 12 weeks, with a 4-week safety follow-up. A total of 259 adult patients with moderate-to-severe plaque psoriasis received ≥1 dose of treatment, with 86% of patients completing the 12-week treatment period.
|
| Key learnings |
|
At 12 weeks, 67% of patients on 30 mg zasocitinib, 68% on 15 mg, 44% on 5 mg, and 18% on 2 mg achieved the primary endpoint of a ≥75% improvement in Psoriasis Area and Severity Index (PASI 75), compared with 6% in the placebo group. |
|
Improved outcomes were seen with higher doses of zasocitinib. Notably, PASI 100, indicating complete skin clearance, was achieved by 33%, 15%, 10% and 2% of patients treated with 30, 15, 5, and 2 mg, respectively, with no patients in the placebo group achieving PASI 100. Similarly, more patients treated with the higher doses achieved a Physician’s Global Assessment of 0 or 1 compared with the lower doses and placebo. |
|
Treatment-emergent adverse events (TEAEs) occurred in 53–62% of patients treated with zasocitinib, compared with 44% of patients treated with placebo. The most common TEAEs were COVID-19, acneiform dermatitis, and diarrhea, with no dose-dependent increase in adverse events observed. |
|
The efficacy and safety profile of zasocitinib seen here suggests it could be a promising oral treatment option for psoriasis, offering an alternative to injectable biologics. An additional benefit is the lack of serious adverse events that are seen with Janus kinase inhibitors. Ongoing phase III trials are underway to confirm these findings. |
- Armstrong A, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: A randomized clinical trial. JAMA Dermatol. 2024. Online ahead of print. DOI: 10.1001/jamadermatol.2024.2701
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox